In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 119139-23-0, name is 3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione, introducing its new discovery. Formula: C20H13N3O2
HISTONE DEACETYLASE INHIBITOR AND PROCESS FOR PRODUCING THE SAME
HDAC inhibitors represented by formula (1) show strong inhibitory activity against various subtypes of HDACs. The compounds of the present invention find utility as pharmaceutical agents for treating or preventing diseases associated with HDAC 1, 4, and 6. The methods for producing the compounds of the present invention enable easy and simple synthesis of various types of these compounds, and are expected to contribute to the development of HDAC inhibitors having novel properties and the like.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 119139-23-0, and how the biochemistry of the body works.Formula: C20H13N3O2
Reference£º
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis